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ORIGINAL RESEARCH
Abstract: The objective was to compare the incidence of adverse reactions reported with
three nonsteroidal anti-inflammatory drugs with different cyclo-oxygenase (COX)-2 selectivity.
All spontaneous adverse reaction notifications in the pharmacovigilance database of the World
Health Organisation Collaborating Centre for International Drug Monitoring with aceclofenac,
meloxicam, and rofecoxib that were recorded during the first year of marketing were included.
The incidence rate (adverse reactions/106 defined daily dose) and 95% confidence interval for
total adverse reactions was 8.7 (6.1–12.0) for aceclofenac, 24.8 (23.1–26.6) for meloxicam,
and 52.6 (49.9–55.4) for rofecoxib. Aceclofenac had a lower incidence of gastrointestinal
bleeding, abdominal pain, and arterial hypertension than meloxicam and a lower incidence of
gastrointestinal bleeding, abdominal pain, liver toxicity, thromboembolic cardiovascular events,
arterial hypertension, and edema than rofecoxib. The incidence of total and gastrointestinal
adverse reactions was significantly lower with aceclofenac than with meloxicam or rofecoxib,
thus raising doubts about the hypothetical advantage of COX-2 selective inhibitors.
Keywords: pharmacovigilance, post-marketing, adverse reactions, nonsteroidal anti-
inflammatory drugs, aceclofenac, meloxicam, rofecoxib
Introduction
The treatment of inflammation and pain is an important area of therapeutics. In the
last decade, nonsteroidal anti-inflammatory drugs (NSAIDs) have played a central
role in these indications and they are currently considered the first choice, being one
of the most widely prescribed drugs. However, their adverse reactions are important;
gastrointestinal toxicity is the most frequent serious adverse effect, causing a
considerable number of hospitalizations and deaths each year around the world (Simon
1995; Peloso 1996; Singh et al 1998; Wolfe et al 1999; Tramer et al 2000).
The effect of NSAIDs is mediated to a large extent by inhibition of prostaglandin
synthesis through cyclo-oxygenase (COX). COX has two iso-enzymes in humans:
COX-1 has a cytoprotective function in the gastric mucosa (Vane and Botting 1998)
and COX-2 is detected in several tissues when an inflammatory reaction takes place.
This has led to the assumption that the anti-inflammatory action of NSAIDs is due to
COX-2 inhibition, whilst the gastric side effects are due to COX-1 inhibition (Vane
1971; Seibert et al 1995; Vane and Botting 1998).
Faced with the possibility of obtaining an anti-inflammatory effect without
damaging the gastric mucosa, COX-2 selective NSAIDs such as celecoxib and
rofecoxib were developed. Demonstration of this supposed advantage was based on
two large safety studies, the CLASS (Celecoxib Long Term Arthritis Study) and the
VIGOR (Vioxx Gastrointestinal Outcomes Research) studies (Bombardier et al 2000;
Silverstein et al 2000). Results from these studies seemed to confirm that the risk of
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secondary gastrointestinal effects was lower with COX-2
selective NSAIDs than with classic NSAIDs. However,
several studies published subsequently have questioned
those results (Mukherjee et al 2001; Hrachavec and Mora
2001; Wright et al 2001; Pedros et al 2002; Laporte et al
2004).
The adverse reactions detected during clinical trials are
not sufficient to completely characterize the safety profile
of a product. The data obtained during the initial years after
the introduction of a new drug to the market allow a better
knowledge of its true safety profile (Caulin 2002; UK MCA
2004). The objective of this study was to compare the
incidence of spontaneous reports of adverse reactions,
recorded in a well established pharmacovigilance system,
during the first year after the introduction of three NSAIDs
with different COX-2 selectivity: aceclofenac, meloxicam,
and rofecoxib.
Methods
We analysed all spontaneous reports of adverse reactions
with the three NSAIDs (aceclofenac, meloxicam, and
rofecoxib) that were recorded through the
pharmacovigilance system in the United Kingdom (UK)
during the first complete year after their introduction to the
market. The UK was selected because, by the time the study
was undertaken, all three drugs had been marketed for more
than one year in this country and because of the reputation
of its pharmacovigilance system. Rofecoxib was selected
as the COX-2 selective NSAID because it was the first to
be introduced and was the best known. Subsequently, it was
decided to incorporate a preferential COX-2 NSAID as
control. Meloxicam was selected as its date of introduction
to the UK market was as close as possible to that of
aceclofenac. According to International Marketing Services
(IMS) Dataview, the dates of introduction to the UK market
were March 1996, September 1996, and May 1999 for
aceclofenac, meloxicam, and rofecoxib, respectively.
Data on adverse reaction reports were obtained from the
World Health Organisation (WHO) Adverse Drug Reaction
database through the WHO Collaborating Centre for
International Drug Monitoring (Uppsala, Sweden). These
data comprise all notifications made directly by physicians
to the Medicines Control Agency (MCA) through the
yellow-card system, and does not include those coming from
pharmaceutical companies.
The adverse reactions reported were coded using
preferred terms (PTs) of the WHO Adverse Reaction
Terminology dictionary (version 2004:4). The analysis was
limited to total adverse reactions and those of the seven
groups of conditions most commonly associated with
NSAIDs: gastrointestinal bleeding, abdominal pain, liver
toxicity, renal toxicity, oedema, arterial hypertension, and
thromboembolic cardiovascular events. The PTs included
in each of these groups are shown in Table 1.
The incidence of adverse reactions was computed by
combining the number of notifications and the exposure
during the corresponding time period. For each of the three
selected drugs, the incidence rate (IR) of the seven types of
adverse reaction considered was computed by dividing the
number of adverse reactions reported by the number of
defined daily doses (DDDs) consumed in the relevant time
period (1997 for aceclofenac and meloxicam, and 2000 for
rofecoxib) and multiplying by 106 (so that rates are
expressed as number of adverse reactions per million DDD).
The number of DDDs consumed of the oral form of each
drug (adopted exposure measure) was estimated from the
sales figures in standard units obtained from the IMS Midas
database and the DDD for each compound. The DDD
Table 1 WHO-ART preferred terms included in the groups assessed
Group WHO-ART preferred terms
Gastrointestinal bleeding Duodenal ulcer hemorrhagic, duodenal ulcer perforated, gastric ulcer hemorrhagic, gastric ulcer
perforated, gastrointestinal hemorrhage, hematemesis, hemorrhage rectum, melaena, esophageal
ulceration hemorrhage, peptic ulcer perforated.
Abdominal pain Abdominal pain
Liver toxicity Bilirubinemia, gamma-GT increased, hepatic function abnormal, hepatitis, hepatitis cholestatic,
hepatocellular damage, jaundice, SGPT increased.
Renal toxicity Nephrosis, oliguria, renal failure acute, renal function abnormal, urine flow decreased.
Edema Angioedema, face edema, edema, edema mouth, edema peripheral, edema periorbital, papilloedema,
tongue edema.
Arterial hypertension Hypertension, hypertension aggravated.
Thromboembolic cardiovascular Angina pectoris aggravated, myocardial infarction, embolism arterial, cerebrovascular disorder, peripheral
events ischemia, thrombophlebitis, thrombophlebitis deep, transient ischemic attack.
Abbreviations: ART, adverse reactions terminology; GT, glutamyl transferase; SGPT, serum glutamic pyruvic transaminase; WHO, World Health Organisation.Therapeutics and Clinical Risk Management 2007:3(2) 227
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established as the minimal daily dose indicated for
maintenance treatment with each product was 200 mg/day
for aceclofenac, 15 mg/day for meloxicam, and 25 mg/day
for rofecoxib (WHO 2004). However, it was decided to
establish an arbitrary dose of 7.5 mg/day (instead of 15 mg/
day) for meloxicam, and 12.5 mg/day (instead of 25 mg/day)
for rofecoxib, since these are the most common dosages
used in everyday practice. This decision necessitated
duplication of the denominator used to compute the IR, so
that it was halved. Consequently, this decision implies a
conservative estimate of the IR with meloxicam and
rofecoxib.
The 95% confidence intervals (CIs) for the IRs were
computed using the exact method based on the Poisson
distribution implemented in the CIA software (BMJ
Publishing, London, UK) (Altman et al 2000). To compare
the IRs of two drugs, the IR ratio (IRR) was computed as
IRR = IRA/IRC, where IRA is the point estimate of the IR
with aceclofenac and IRC is the point estimate of the IR
with the comparator drug (meloxicam or rofecoxib). The
95% CIs for the IRRs were computed using an exact method
based on the Poisson distribution 21 implemented in a SAS
®
(v8.00) program (SAS Institute, Inc., Cary, NC, USA). The
functions used in this SAS program were validated by
reproducing example 9.2 from the book by Sahai and
Khurshid (1996).
Due to the possibility of a bias resulting from secular
trends affecting spontaneous reporting of adverse reactions
in the period considered (from 1997, for aceclofenac and
meloxicam, to 2000 for rofecoxib), we looked at the yearly
global report rate during this period. Since the number of
adverse reaction notifications showed a progressive increase
in the period from 1996 to 2000, an adjustment was made
to mitigate possible bias. To this end, we re-computed the
IR of rofecoxib (and the IRR of aceclofenac vs rofecoxib)
adjusting the rates for rofecoxib, to compensate for the
relative over-reporting in 2000 with respect to 1997, as
follows: adjusted IR = IR x 0.82. The correction factor of
0.82 was obtained by dividing the total number of adverse
reaction reports in 1997 (174 543) by the corresponding
number in 2000 (213 206).
Results
In the WHO database, a total of 36 adverse reactions were
recorded with aceclofenac and 769 with meloxicam during
1997, and 1743 with rofecoxib during 2000.
During 1997, the number of units sold in the UK was
138 400 for aceclofenac (PRESERVEX, 60 tablets 100 mg)
and 867 300 for meloxicam (MOBIC, 30 tablets 7.5 mg/30
tablets 15 mg/12 suppositories 15 mg). In 2000, 592 000
units of rofecoxib (VIOXX, 28 tablets 12.5 mg/28 tablets
25 mg) were sold. These consumption data imply an
exposure of 4 152 000 DDD for aceclofenac, 30 963 000
DDD for meloxicam and 27 104 000 DDD for rofecoxib.
The IRs (95% CI) of all adverse reactions per million
DDD were 8.7 (6.1–12.0) for aceclofenac, 24.8 (23.1–26.6)
for meloxicam and 52.6 (49.9–55.4) for rofecoxib. The IRs
of adverse reactions for each of the seven groups considered
are shown in Table 2. In general, the IRs with aceclofenac
were lower than those with meloxicam or rofecoxib for
gastrointestinal events and hypertension, whilst those for
liver and renal toxicity, thromboembolic events and oedema
were lower with meloxicam than with aceclofenac. In all
cases except renal toxicity, the highest incidence was
observed with rofecoxib, even after adjustment for the
Table 2 Incidence rates (95% confidence interval [CI]) of
spontaneous reports of adverse reactions with aceclofenac,
meloxicam, and rofecoxib during the first year after
introduction to the UK market
Adverse reaction Incidence rate Adjusted
group (95% CI) incidence rate
(95% CI)
Gastrointestinal bleeding
Aceclofenac 0.000 (0.000–0.888)
Meloxicam 1.421 (1.033–1.908)
Rofecoxib 3.247 (2.604–4.000) 2.656 (2.078–3.345)
Abdominal pain
Aceclofenac 0.000 (0.000–0.888)
Meloxicam 1.356 (0.978–1.833)
Rofecoxib 3.837 (3.135–4.649) 3.136 (2.505–3.878)
Liver toxicity
Aceclofenac 0.241 (0.006–1.342)
Meloxicam 0.032 (0.001–0.180)
Rofecoxib 0.775 (0.480–1.184) 0.627 (0.365–1.004)
Renal toxicity
Aceclofenac 0.723 (0.149–2.112)
Meloxicam 0.097 (0.020–0.283)
Rofecoxib 0.627 (0.365–1.004) 0.517 (0.282–0.867)
Thromboembolic cardiovascular events
Aceclofenac 0.241 (0.006–1.342)
Meloxicam 0.065 (0.008–0.233)
Rofecoxib 0.664 (0.394–1.050) 0.553 (0.310–0.913)
Arterial hypertension
Aceclofenac 0.000 (0.000–0.888)
Meloxicam 0.097 (0.020–0.283)
Rofecoxib 0.701 (0.422–1.095) 0.590 (0.337–0.959)
Edema
Aceclofenac 1.204 (0.391–2.810)
Meloxicam 1.130 (0.787–1.572)
Rofecoxib 4.833 (4.041–5.735) 3.948 (3.235–4.77)Therapeutics and Clinical Risk Management 2007:3(2) 228
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positive secular trend in the overall number of adverse
reaction reports.
The IRRs of aceclofenac versus meloxicam and of
aceclofenac versus rofecoxib are displayed in Table 3. A CI
excluding unity reflects a significant difference in the IR
between the two drugs being compared. In the case of
gastrointestinal bleeding and abdominal pain, the IR was
significantly lower with aceclofenac than with meloxicam
or rofecoxib. In the case of edema, the IR with aceclofenac
was significantly lower than with rofecoxib. In the remaining
cases, the width of the CI does not allow conclusive
differences to be established.
Discussion
The data in this study are based on spontaneous reports of
adverse reactions recorded through the pharmacovigilance
system in the UK. This allows for a fair comparative
assessment of post-marketing safety information since the
same notification system is used for all three drugs. The
UK was selected because all three NSAIDs were already
marketed, the times at which they were introduced to the
market were relatively close, and finally because of the good
reputation of the UK yellow-card pharmacovigilance
system.
Although pharmacovigilance is an essential process to
establish the safety of a drug and to detect rare adverse
reactions, the analysis of pharmacovigilance data has
important limitations. Firstly, the information is not always
homogeneous, at least in terms of the source (which is not
always available). Secondly, under-reporting is very
common. Finally, the difficulty in establishing a causal
relationship between the adverse reaction and the drug
administered is possibly the most serious limitation. It is
important to bear in mind that, in the case of spontaneous
reports, much of the data needed for a causality assessment,
including chronology and the possible contribution of
concomitant medications and diseases, are not always
available. For these reasons, the WHO states that studies
such as the one presented here do not necessarily reflect
their opinion. In any case, these limitations are inherent to
the pharmacovigilance system itself, and cannot be
overcome when data from such systems are analyzed.
When pharmacovigilance data are used, as in the current
study, to compare the safety profiles of different drugs, it is
important to take into account that the frequency of
notifications is dependent on the time elapsed since the
introduction to the market, typically reaching a maximum
by the end of the second year and subsequently decreasing.
To avoid a biased comparison due to this time evolution
pattern, the first year after the introduction of each drug
was studied. It is also important to adjust for possible secular
trends in the reporting, as we did for the adverse reactions
reported with rofecoxib during 2000.
The number of notifications with a product may be
influenced by advertising and may depend on the expectation
and degree of awareness of physicians and other health
professionals (Malhotra et al 2004). Unfortunately, there is
no simple and reliable way to measure these factors so that
they may be taken into account.
This study shows that the incidence of spontaneous
reports of adverse reactions with aceclofenac is, in general,
lower than it is with the comparators, particularly rofecoxib.
This is surprising since rofecoxib is a selective COX-2
inhibitor and, consequently, a better gastrointestinal
safety profile might be expected. Although, presumably,
there could be a trend for rofecoxib to be prescribed for
patients with a higher gastrointestinal risk, our findings
do not confirm the hypothetical advantage for rofecoxib
at the gastrointestinal level, but instead suggest the
possibility that its safety profile is still inferior to that of
aceclofenac.
Table 3 Incidence rate ratios (95% confidence intervals [CI])
of adverse reactions with aceclofenac versus meloxicam, and
with aceclofenac versus rofecoxib
Adverse reaction Incidence rate Adjusted
group ratio (95% CI) incidence rate
ratio (95% CI)
Gastrointestinal bleeding
Aceclofenac/meloxicam 0.00 (0.00–0.65)
Aceclofenac/Rofecoxib 0.00 (0.00–0.28) 0.00 (0.00–0.34)
Abdominal pain
Aceclofenac/meloxicam 0.00 (0.00–0.68)
Aceclofenac/rofecoxib 0.00 (0.00–0.24) 0.00 (0.00–0.29)
Liver toxicity
Aceclofenac/meloxicam 7.46 (0.10–585.39)
Aceclofenac/rofecoxib 0.31 (0.01–1.93) 0.38 (0.01–2.45)
Renal toxicity
Aceclofenac/meloxicam 7.46 (1.00–55.68)
Aceclofenac/rofecoxib 1.15 (0.22–3.98) 1.40 (0.26–5.01)
Thromboembolic cardiovascular events
Aceclofenac/meloxicam 3.73 (0.06–71.62)
Aceclofenac/rofecoxib 0.36 (0.01–2.30) 0.43 (0.01–2.83)
Arterial hypertension
Aceclofenac/meloxicam 0.00 (0.00–18.05)
Aceclofenac/Rofecoxib 0.00 (0.00–1.40) 0.00 (0.00–1.69)
Edema
Aceclofenac/meloxicam 1.07 (0.33–2.73)
Aceclofenac/rofecoxib 0.25 (0.08–0.60) 0.31 (0.10–0.73)Therapeutics and Clinical Risk Management 2007:3(2) 229
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The results of the study suggest that aceclofenac may
have a significantly lower risk of gastrointestinal bleeding,
abdominal pain and oedema than meloxicam or rofecoxib.
Due to the nature and source of the data used, there is
no guarantee that the results reflect the real incidence of
adverse reactions, and therefore it is not possible to
definitively conclude that aceclofenac has a lower incidence
of gastrointestinal bleeding or abdominal pain than
meloxicam or rofecoxib. For instance, the expectation
gained from previous results that rofecoxib has a better
gastrointestinal safety profile might have induced a bias if
it was preferentially indicated in high risk patients
(“channeling bias”) (Wolfe, Flowers, et al 2002; MacDonald
et al 2003) or if proton-pump inhibitors were less frequently
used in association. Thus, in a study conducted in the UK
that compared two cohorts of 1127 and 1376 patients treated
with rofecoxib and meloxicam, respectively, gastrointestinal
antecedents were more common in the cohort treated with
rofecoxib, but the IRs of upper gastrointestinal
complications were not significantly different after
adjustment for this risk factor (Layton et al 2003). However,
in a recent study conducted in 18 hospitals in Spain and
Italy that analyzed 2813 cases and 7193 controls, neither
the risk profile nor the use of gastric protectors differed
between patients treated with rofecoxib and those given
aceclofenac (Laporte et al 2004). Therefore, a selection bias
does not always appear to be present, although the number
of patients exposed to the newer NSAID was small. Other
studies have reported the existence of possible channeling
bias for GI effects or use of gastroprotective agents (Wolfe,
Flowers, et al 2002; Moride et al 2005), severity of illness
and cardiovascular risk (paradoxically patients at higher risk
were channeled to COX-2 inhibitors) (Zhao et al 2002;
Rawson et al 2005).
In a study that analyzed 106 564 patients starting
treatment with a NSAID, proton pump inhibitors were more
frequently given with COX-2 inhibitors than with traditional
NSAIDs (Ofman et al 2004). However, in a similar study
based on data from 69 648 patients, the use of proton pump
inhibitors was less common in patients treated with COX-2
inhibitors that in those treated with traditional NSAIDs.
Unfortunately, we cannot know whether or not this
phenomenon affected our data or, if so, how it was affected.
Finally, the previously mentioned study of cases and controls
reported estimates of gastrointestinal bleeding risk of 1.4
per million cases for aceclofenac, 5.7 for meloxicam, and
7.2 for rofecoxib (Laporte et al 2002). This safety profile
pattern is comparable with the one observed in our study.
In summary, we would like to draw attention to the
usefulness of the safety alert system. Recently, we have seen
the unexpected withdrawal of Vioxx
® based on an
unforeseen cardiovascular risk (Merck 2004). This fact has
triggered the risk/benefit re-evaluation of this therapeutic
class by the main regulatory agencies (Okie 2005).
The use of this type of pharmacovigilance raw data
analysis might contribute to early characterization of the
safety profile knowledge of such drugs.
Conclusions
Spontaneous reports of adverse reactions recorded during
the first year after introduction of aceclofenac, meloxicam,
and rofecoxib in the UK revealed IRs of total adverse
reactions, gastrointestinal bleeding, abdominal pain, and
edema that are notably lower for aceclofenac than for
meloxicam or rofecoxib. Although the nature of the data
does not guarantee that these results reflect a real lower
incidence of these reactions with aceclofenac, the magnitude
of the differences observed provide a clear indication that
the hypothetical advantage of COX-2 selective inhibitors
may not translate into clinical safety advantages regarding
gastrointestinal bleeding or overall safety.
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